2021年8月24日 · With this approval, XARELTO ® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in patients with coronary artery disease (CAD) and major thrombotic vascular events, such as myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology, in patients with ...

2025年1月22日 · Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in...

2023年3月5日 · XARELTO ® is the first and only anticoagulant approved in combination with aspirin for reducing the risk of major thrombotic vascular events * in patients with peripheral artery disease (PAD)

2022年8月27日 · Randomized clinical trials have shown that these non–vitamin K antagonist oral anticoagulants are as effective as vitamin K antagonist therapy for stroke prevention and have a lower risk of...

2023年11月12日 · It is the longest and largest trial to-date comparing factor XI inhibitors to the current standard of care use of direct-acting oral anticoagulants. The analysis found that abelacimab substantially reduced bleeding among people …

A new class of anticoagulant drugs on the horizon is taking fresh aim at one of cardiology’s toughest challenges: how to prevent blood clots that cause heart attacks and strokes, without...

2015年3月19日 · The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for many indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxab...

2020年10月26日 · XARELTO ®, in combination with aspirin, was approved by the FDA in 2018 to reduce the risk of major CV events in patients with chronic PAD and coronary artery disease (CAD) – the only direct oral anticoagulant (DOAC) approved for use in these populations.

2023年3月5日 · The XARELTO ® vascular dose is the first and only approved anticoagulant for PAD. XARELTO ® acts on a dual pathway inhibition (DPI) approach to target both clotting mechanisms, thrombin and platelet activation.

Learn more about how XARELTO can help: How does XARELTO work? XARELTO slows your body's ability to clot by selectively blocking one of the clotting factors found in your blood—an …